SG11201703803WA - Targeted xten conjugate compositions and methods of making same - Google Patents
Targeted xten conjugate compositions and methods of making sameInfo
- Publication number
- SG11201703803WA SG11201703803WA SG11201703803WA SG11201703803WA SG11201703803WA SG 11201703803W A SG11201703803W A SG 11201703803WA SG 11201703803W A SG11201703803W A SG 11201703803WA SG 11201703803W A SG11201703803W A SG 11201703803WA SG 11201703803W A SG11201703803W A SG 11201703803WA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- making same
- conjugate compositions
- xten conjugate
- targeted
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462078171P | 2014-11-11 | 2014-11-11 | |
US201562119483P | 2015-02-23 | 2015-02-23 | |
US201562211378P | 2015-08-28 | 2015-08-28 | |
PCT/US2015/060230 WO2016077505A2 (en) | 2014-11-11 | 2015-11-11 | Targeted xten conjugate compositions and methods of making same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201703803WA true SG11201703803WA (en) | 2017-06-29 |
Family
ID=55955256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201703803WA SG11201703803WA (en) | 2014-11-11 | 2015-11-11 | Targeted xten conjugate compositions and methods of making same |
Country Status (14)
Country | Link |
---|---|
US (1) | US20180125988A1 (en) |
EP (1) | EP3218390A4 (en) |
JP (1) | JP2018500049A (en) |
KR (1) | KR20170083095A (en) |
CN (1) | CN107207564A (en) |
AU (1) | AU2015346330A1 (en) |
BR (1) | BR112017009951A2 (en) |
CA (1) | CA2964968A1 (en) |
EA (1) | EA201790871A1 (en) |
IL (1) | IL251823A0 (en) |
MX (1) | MX2017006016A (en) |
PH (1) | PH12017500866A1 (en) |
SG (1) | SG11201703803WA (en) |
WO (1) | WO2016077505A2 (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016315656A1 (en) | 2015-08-28 | 2018-02-01 | Amunix Pharmaceuticals, Inc. | Chimeric polypeptide assembly and methods of making and using the same |
KR102444614B1 (en) * | 2016-03-22 | 2022-09-21 | 에프. 호프만-라 로슈 아게 | Protease-activated T cell bispecific molecule |
DK3433280T3 (en) | 2016-03-22 | 2023-06-19 | Hoffmann La Roche | Protease-activated T-cell bispecific molecules |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
SG11201811290VA (en) | 2016-06-17 | 2019-01-30 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117+cells |
TWI797097B (en) | 2016-11-28 | 2023-04-01 | 日商中外製藥股份有限公司 | Polypeptides comprising an antigen-binding domain and a transport moiety |
WO2018119196A1 (en) | 2016-12-23 | 2018-06-28 | Immunogen, Inc. | Immunoconjugates targeting adam9 and methods of use thereof |
US11242402B2 (en) | 2016-12-23 | 2022-02-08 | Macrogenics, Inc. | ADAM9-binding molecules, and methods of use thereof |
WO2018134787A2 (en) | 2017-01-20 | 2018-07-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd137+ cells |
BR112019016553A2 (en) * | 2017-02-10 | 2020-03-31 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND PSMA, NKG2D AND CD16 |
JP7166278B2 (en) * | 2017-03-30 | 2022-11-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination of anti-PD-L1 antibody and DNA-PK inhibitor for cancer treatment |
US11939385B2 (en) * | 2017-05-16 | 2024-03-26 | ALX Oncology Inc. | Activatable antibodies and methods of use thereof |
WO2019023164A1 (en) * | 2017-07-24 | 2019-01-31 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing protein function |
CN111356477A (en) | 2017-08-01 | 2020-06-30 | Ab工作室有限公司 | Bispecific antibodies and uses thereof |
BR112020010248A2 (en) * | 2017-11-28 | 2020-11-10 | Chugai Seiyaku Kabushiki Kaisha | ligand binding molecule having adjustable ligand binding activity |
WO2019147338A2 (en) | 2017-11-28 | 2019-08-01 | Board Of Regents Of The University Of Nebraska | Radiopharmaceuticals and methods of use thereof |
BR112020012220A2 (en) * | 2017-12-21 | 2021-01-26 | Amunix Pharmaceuticals, Inc. | release segments and connection compositions comprising the same |
AU2019286396A1 (en) * | 2018-06-14 | 2020-12-17 | Bioatla, Inc. | Multi-specific antibody constructs |
JP7477885B2 (en) | 2018-06-22 | 2024-05-02 | キュージーン インコーポレイテッド | Cytokine-based bioactive agents and methods of use thereof |
CA3104511A1 (en) | 2018-06-26 | 2020-01-02 | Immunogen, Inc. | Immunoconjugates targeting adam9 and methods of use thereof |
BR112021000673A2 (en) * | 2018-07-18 | 2021-04-20 | Genentech, Inc. | methods for treating an individual with lung cancer, kits, anti-pd-l1 antibody and compositions |
JP2022532342A (en) | 2019-05-14 | 2022-07-14 | ニューベイション・バイオ・インコーポレイテッド | Anti-cancer nuclear hormone receptor targeting compound |
EP3983446A4 (en) * | 2019-06-11 | 2023-04-19 | BioAtla, Inc. | Conditionally active anti-epcam antibodies, antibody fragments, their immunoconjugates and uses thereof |
WO2020261221A1 (en) * | 2019-06-26 | 2020-12-30 | Waters Technologies Corporation | Coatings with immobilized affinity ligands and enzymes and use thereof in liquid chromatography assays |
CN112569368A (en) * | 2019-08-07 | 2021-03-30 | 烟台迈百瑞国际生物医药股份有限公司 | Antibody drug conjugate and application thereof |
WO2021041300A2 (en) * | 2019-08-23 | 2021-03-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
US20230287040A1 (en) * | 2019-11-13 | 2023-09-14 | Amunix Pharmaceuticals, Inc. | Barcoded xten polypeptides and compositions thereof, and methods for making and using the same |
CN113597434B (en) | 2019-12-31 | 2022-07-01 | 北京质肽生物医药科技有限公司 | Fusion proteins of GLP-1 and GDF15 and conjugates thereof |
CN113728013B (en) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Conjugates of fusion proteins of GLP-1 and FGF21 |
BR112022026420A2 (en) * | 2020-06-25 | 2023-04-18 | Amunix Pharmaceuticals Inc | HER-2 TARGETED BISPECIFIC COMPOSITIONS AND METHODS FOR PREPARING AND USING THEM |
US11512113B2 (en) | 2020-08-11 | 2022-11-29 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
CN115925995A (en) | 2020-09-30 | 2023-04-07 | 北京质肽生物医药科技有限公司 | Polypeptide Conjugates and Methods of Use |
TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
WO2022178754A1 (en) * | 2021-02-25 | 2022-09-01 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates with therapeutic agents and oligonucleotides and uses thereof |
EP4304660A1 (en) | 2021-03-08 | 2024-01-17 | ImmunoGen, Inc. | Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer |
MX2023011241A (en) | 2021-03-23 | 2023-10-03 | Nuvation Bio Inc | Anti-cancer nuclear hormone receptor-targeting compounds. |
CN113215195B (en) * | 2021-04-30 | 2023-04-11 | 四川大学 | Recombinant expression vector for high-expression SIA in myogenic cell specificity and application thereof |
EP4334314A1 (en) | 2021-05-03 | 2024-03-13 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
WO2022256507A1 (en) * | 2021-06-04 | 2022-12-08 | Immunogen, Inc. | Treatment of cancer in patients with soluble fr-alpha |
CN114672450B (en) * | 2022-01-26 | 2022-11-11 | 中山大学附属第一医院 | Method for separating and purifying theca cells |
WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
WO2024020486A2 (en) * | 2022-07-20 | 2024-01-25 | Fuse Biotherapeutics Inc. | Receptor tyrosine kinase-like orphan receptor 1 (ror1)-specific vhh antibodies and multispecific antibodies thereof as immune cell engagers |
CN118126116A (en) * | 2022-12-01 | 2024-06-04 | 核欣(苏州)医药科技有限公司 | Heterodimer and radiopharmaceutical application thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7355019B2 (en) * | 2000-06-06 | 2008-04-08 | Sibtech, Inc. | Cysteine-containing peptide tag for site-specific conjugation of proteins |
US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US8383767B2 (en) * | 2008-06-27 | 2013-02-26 | Academia Sinica | Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain |
MX362028B (en) * | 2009-02-03 | 2019-01-04 | Amunix Pharmaceuticals Inc | Extended recombinant polypeptides and compositions comprising same. |
MX354555B (en) * | 2009-06-08 | 2018-03-09 | Amunix Operating Inc | Growth hormone polypeptides and methods of making and using same. |
MX366864B (en) * | 2012-02-27 | 2019-07-26 | Amunix Operating Inc | Xten conjugate compositions and methods of making same. |
US20130316946A1 (en) * | 2012-05-24 | 2013-11-28 | Cebix, Inc. | Extended recombinant polypeptide-modified c-peptide |
-
2015
- 2015-11-11 US US15/525,819 patent/US20180125988A1/en not_active Abandoned
- 2015-11-11 AU AU2015346330A patent/AU2015346330A1/en not_active Abandoned
- 2015-11-11 EP EP15858371.6A patent/EP3218390A4/en not_active Withdrawn
- 2015-11-11 CN CN201580073115.6A patent/CN107207564A/en active Pending
- 2015-11-11 MX MX2017006016A patent/MX2017006016A/en unknown
- 2015-11-11 WO PCT/US2015/060230 patent/WO2016077505A2/en active Application Filing
- 2015-11-11 JP JP2017544574A patent/JP2018500049A/en active Pending
- 2015-11-11 EA EA201790871A patent/EA201790871A1/en unknown
- 2015-11-11 BR BR112017009951A patent/BR112017009951A2/en not_active Application Discontinuation
- 2015-11-11 SG SG11201703803WA patent/SG11201703803WA/en unknown
- 2015-11-11 KR KR1020177015658A patent/KR20170083095A/en unknown
- 2015-11-11 CA CA2964968A patent/CA2964968A1/en not_active Abandoned
-
2017
- 2017-04-20 IL IL251823A patent/IL251823A0/en unknown
- 2017-05-10 PH PH12017500866A patent/PH12017500866A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL251823A0 (en) | 2017-07-31 |
EP3218390A4 (en) | 2018-11-21 |
CA2964968A1 (en) | 2016-05-19 |
JP2018500049A (en) | 2018-01-11 |
MX2017006016A (en) | 2017-06-19 |
US20180125988A1 (en) | 2018-05-10 |
KR20170083095A (en) | 2017-07-17 |
WO2016077505A3 (en) | 2016-07-21 |
AU2015346330A1 (en) | 2017-05-11 |
CN107207564A (en) | 2017-09-26 |
BR112017009951A2 (en) | 2017-12-26 |
EP3218390A2 (en) | 2017-09-20 |
EA201790871A1 (en) | 2017-11-30 |
PH12017500866A1 (en) | 2017-11-06 |
WO2016077505A2 (en) | 2016-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL251823A0 (en) | Targeted xten conjugate compositions and methods of making same | |
HRP20192145T1 (en) | Carrier-antibody compositions and methods of making and using the same | |
EP3436061A4 (en) | Saccharide-polypeptide conjugate compositions and methods of use thereof | |
ZA201702794B (en) | Cellulose-containing compositions and methods of making same | |
EP3194564A4 (en) | Trichoderma compositions and methods of use | |
EP3166892A4 (en) | Scale-inhibition compositions and methods of making and using the same | |
EP3151678A4 (en) | Soluble protein compositions and methods of their making | |
ZA202005857B (en) | Oligonucleotide compositions and methods of making the same | |
EP3190886A4 (en) | Compositions and methods of use thereof | |
HK1250345A1 (en) | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same | |
EP3253396A4 (en) | Probiotic compositions and methods of use | |
HK1243404A1 (en) | Tryptamide compositions and methods of use | |
GB201509023D0 (en) | Compositions and methods of production thereof | |
IL261794A (en) | Compositions and methods of their use | |
PL3445730T3 (en) | Stone-glass macrocomposites and compositions and methods of making | |
AU2015905131A0 (en) | Methods and Preparation and Uses of Xanthorrhoeaceae Compositions | |
AU2014904994A0 (en) | Methods and Preparation and Uses of Xanthorrhoeaceae Compositions | |
AU2014905067A0 (en) | Compositions and methods of use | |
AU2014902829A0 (en) | Compositions and Methods of Use | |
GB201419559D0 (en) | Therapeutic compositions and methods | |
AU2014901633A0 (en) | Compositions and methods of production and use thereof |